Fig. 1From: Growth hormone treatment improves final height in children with X-linked hypophosphatemiaHeight SDS in children with X-linked hypophosphatemia from diagnosis to adult height. Changes in height of children with XLH who received rhGH are plotted with the red dotted line. Children treated with rhGH were diagnosed with XLH at a mean age of 3.4 years. The rhGH treatment was started at average of 9.8 years and discontinued at average of 14.2 years. The age at last visit was ~ 19.2 years. Changes in height of children with XLH who did not receive rhGH are plotted with the blue line. The children in this cohort were diagnosed with XLH at a mean age of 2.6 years. The age at last visit was at average of 16.9 years. *p < 0.001. XLH: X-linked hypophosphatemia; SDS: standard deviation score or Z-score; rhGH: recombinant human growth hormoneBack to article page